Progyny (NASDAQ:PGNY – Get Rating) updated its FY 2022 earnings guidance on Monday. The company provided earnings per share guidance of $0.07-$0.14 for the period, compared to the consensus earnings per share estimate of $0.12. The company issued revenue guidance of $735.00 million-$775.00 million, compared to the consensus revenue estimate of $754.06 million.Progyny also updated its Q2 2022 guidance to $0.01-$0.02 EPS.
Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Progyny from a hold rating to a buy rating and set a $38.00 target price on the stock in a report on Thursday. TheStreet lowered shares of Progyny from a c- rating to a d+ rating in a report on Friday, January 28th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Buy and an average price target of $65.86.
Shares of PGNY stock opened at $36.94 on Monday. Progyny has a 12 month low of $32.06 and a 12 month high of $68.32. The firm has a market capitalization of $3.40 billion, a P/E ratio of 65.96, a P/E/G ratio of 18.46 and a beta of 2.01. The company’s fifty day moving average price is $43.58 and its two-hundred day moving average price is $46.35.
In other Progyny news, Director Norman Payson sold 8,330 shares of the company’s stock in a transaction dated Wednesday, February 23rd. The shares were sold at an average price of $35.30, for a total value of $294,049.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Anevski sold 17,569 shares of the company’s stock in a transaction dated Tuesday, February 15th. The stock was sold at an average price of $41.39, for a total transaction of $727,180.91. The disclosure for this sale can be found here. In the last 90 days, insiders sold 540,384 shares of company stock worth $22,977,294. Company insiders own 14.00% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC bought a new position in Progyny in the 1st quarter worth about $62,000. Parkside Financial Bank & Trust bought a new position in Progyny in the 1st quarter worth about $70,000. Mackenzie Financial Corp bought a new position in Progyny in the 1st quarter worth about $216,000. Cetera Investment Advisers grew its position in Progyny by 4.4% in the 4th quarter. Cetera Investment Advisers now owns 6,359 shares of the company’s stock worth $320,000 after purchasing an additional 270 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of Progyny by 25.2% in the 1st quarter. Bank of Montreal Can now owns 7,278 shares of the company’s stock worth $381,000 after acquiring an additional 1,465 shares during the period. Hedge funds and other institutional investors own 82.51% of the company’s stock.
Progyny Company Profile (Get Rating)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- Recession Fears Mount After Weak Manufacturing Data
- WD-40 Stock is Ready to Coil like a Piston
- CarMax Stock is Poised to Bounce
- F5 Inc Is a Troubled Stock With Upside Potential
- Cloudflare Inc: Struggling but With Great Opportunities
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.